Noxafil
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Les medicaments sont indispensables pour la sante mais leur usage n’est pas anodin. Les indications autorisees du dossier d’AMM d…
Objectives: Compare the cost of the primary prophylaxis of invasive fungal infections (IFI) with voriconazole, posaconazole, and…
X-ray Powder Diffraction (XRPD) and micro-Raman Spectroscopy were applied in the present work in order to develop methods capable…
Invasive antifungal infections are reasons for morbidity and mortality in immunogenic patients worldwide. Posaconazole is a most…
A 52‐year‐old woman with pulmonary sarcoidosis on immunosuppressive therapy developed pulmonary infiltrates and cutaneous…
Posaconazole (SCH 56592) is a novel triazole antifungal drug that is marketed in Europe and the United States under the trade…
The incidence of fungal infections has dramatically increased in the past few decades.1,2 These infections contribute…
Posaconazole (Noxafil, SCH 56592), an orally available broad-spectrum triazole antifungal, is currently in phase III clinical…
Posaconazole [SCH 56592, SPRIAFIL, Noxafil] is an orally active triazole derivative that is in phase III trials with the Schering…